---
layout: default
title: Ethynodiol Diacetate
description: "Ethynodiol Diacetate 的老藥新用潛力分析。模型預測等級 L5，包含 6 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 僅模型預測 (L5)
nav_order: 68
evidence_level: L4
indication_count: 6
---

# Ethynodiol Diacetate

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L5</strong> | 預測適應症: <strong>6</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ethynodiol Diacetate 藥師評估筆記

## 一句話總結

<p class="key-answer" data-question="Ethynodiol Diacetate 可以用於治療什麼新適應症？">
Ethynodiol diacetate 是一種口服避孕藥成分，TxGNN 預測其可能用於痤瘡治療，此預測具有文獻支持且機轉合理。
</p>


## 快速總覽

| 項目 | 內容 |
|------|------|
| 藥物名稱 | Ethynodiol Diacetate |
| DrugBank ID | DB00823 |
| 台灣商品名 | 亞卡南爾非滅錠 |
| 原核准適應症 | 避孕、抑制排卵、月經異常 |
| 預測新適應症 | 痤瘡(acne)、女性不孕症 |
| 最高預測分數 | 0.9957 (acne) |
| 證據等級 | L3 (觀察性研究) |





## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. acne (disease)</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.57%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p>Ethynodiol diacetate 作為 19-nortestosterone 衍生物，其對痤瘡的潛在療效有明確的藥理學基礎：</p>

<ol>
<li><strong>抗雄激素機轉</strong>：口服避孕藥可降低游離睪固酮濃度，減少皮脂腺活性</li>
<li><strong>SHBG 增加</strong>：雌激素成分增加性荷爾蒙結合球蛋白(SHBG)，降低雄激素生物活性</li>
<li><strong>皮脂分泌減少</strong>：減少皮脂分泌是治療痤瘡的關鍵機轉</li>
<li><strong>臨床經驗支持</strong>：多種口服避孕藥已獲 FDA 核准用於痤瘡治療</li>
</ol>

<h3>臨床試驗</h3>

<p>目前無針對此特定適應症的臨床試驗登記。</p>

<h3>相關文獻</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7825629/" target="_blank">7825629</a></td><td>1995</td><td>Article</td><td>The American journal of medici</td><td>The androgenicity of progestins.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2046083/" target="_blank">2046083</a></td><td>1991</td><td>Article</td><td>The Journal of reproductive me</td><td>Complexion changes in oral contraceptive users. Results from a phase IV multicen...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6220224/" target="_blank">6220224</a></td><td>1983</td><td>Article</td><td>The New England journal of med</td><td>Androgen excess in cystic acne.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12254865/" target="_blank">12254865</a></td><td>1964</td><td>Article</td><td>JAMA</td><td>Effect of cyclic progestin-estrogen therapy on sebum and acne in women.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/371370/" target="_blank">371370</a></td><td>1979</td><td>Article</td><td>Advances in internal medicine</td><td>Clinical pharmacology of the steroidal oral contraceptives.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12256240/" target="_blank">12256240</a></td><td>1972</td><td>Article</td><td>Gyogyszereink</td><td>Experiences in dermatology with various contraceptives containing gestagen.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/966242/" target="_blank">966242</a></td><td>1976</td><td>Article</td><td>The Journal of reproductive me</td><td>Changes in sexual drives of patients on oral contraceptives.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4254668/" target="_blank">4254668</a></td><td>1971</td><td>Article</td><td>Therapeutique (La Semaine des </td><td>[Trial treatment of seborrhea and of common acne in females with the ovulation i...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4252699/" target="_blank">4252699</a></td><td>1970</td><td>Article</td><td>Zentralblatt fur Gynakologie</td><td>[Effect of various ovulation inhibitors in different female constitutional types...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12266609/" target="_blank">12266609</a></td><td>1984</td><td>Article</td><td>Contraception, fertilite, sexu</td><td>[How to choose an oral contraceptive in 1984].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/5459598/" target="_blank">5459598</a></td><td>1970</td><td>Article</td><td>Ginekologia polska</td><td>[Clinical aspects of Ovulen application as a contraceptive and in gynecological ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. female infertility</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.31%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（13 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12317413/" target="_blank">12317413</a></td><td>1987</td><td>Article</td><td>Current therapeutics</td><td>Oral contraceptives.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/786744/" target="_blank">786744</a></td><td>1976</td><td>Article</td><td>Fertility and sterility</td><td>Carbohydrate metabolism in male infertility and female fertility-control patient...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/5639193/" target="_blank">5639193</a></td><td>1968</td><td>Article</td><td>Obstetrics and gynecology</td><td>The oversuppression syndrome.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2128711/" target="_blank">2128711</a></td><td>1990</td><td>Article</td><td>Obstetrics and gynecology clin</td><td>Modern trends in contraception.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14238631/" target="_blank">14238631</a></td><td>1965</td><td>Article</td><td>Bibliotheca gynaecologica</td><td>[STUDIES ON THE ACTION AND SIDE EFFECTS OF NORETHYNODREL AND ETHYNODIOL DIACETAT...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4135338/" target="_blank">4135338</a></td><td>1974</td><td>Article</td><td>Current medical research and o</td><td>A visual aid to the classification of oral contraceptives.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1566635/" target="_blank">1566635</a></td><td>1992</td><td>Article</td><td>Acta pharmaceutica Hungarica</td><td>[The effect of oral ovulation inhibiting (mono-, bi- and triphase) contraceptive...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4114467/" target="_blank">4114467</a></td><td>1972</td><td>Article</td><td>American journal of obstetrics</td><td>The effect of intrauterine devices, oral contraceptives, estrogens, and progesto...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6067922/" target="_blank">6067922</a></td><td>1967</td><td>Article</td><td>Journal of reproduction and fe</td><td>Effect of Sc. 11800 (ethynodiol diacetate) on the genital tract of women.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4813805/" target="_blank">4813805</a></td><td>1974</td><td>Article</td><td>American journal of obstetrics</td><td>Endometriosis: treatment with hormonal pseudopregnancy and-or operation.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14339443/" target="_blank">14339443</a></td><td>1964</td><td>Article</td><td>Die Medizinische Welt</td><td>[HORMONAL OVULATION INHIBITION WITH OVULEN].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14163475/" target="_blank">14163475</a></td><td>1964</td><td>Article</td><td>Annales d&#x27;endocrinologie</td><td>[ETHYNODIOL DIACETATE (SC 11800) IN THE TREATMENT OF LUTEAL INSUFFICIENCY].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/5722983/" target="_blank">5722983</a></td><td>1968</td><td>Article</td><td>Zentralblatt fur Gynakologie</td><td>[Cytologic and colposcopic findings before and after administration of ovulation...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. 46,XY disorder of sex development due to testicular steroidogenesis defect</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.19%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. longitudinal vaginal septum</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.09%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. transverse vaginal septum</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.09%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. eye disease</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.01%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（10 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/791557/" target="_blank">791557</a></td><td>1976</td><td>Article</td><td>Clinical obstetrics and gyneco</td><td>Current status of oral contraceptive steroids.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4206444/" target="_blank">4206444</a></td><td>1973</td><td>Article</td><td>Annals of clinical research</td><td>Ocular side-effects of oral contraceptives.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4452242/" target="_blank">4452242</a></td><td>1974</td><td>Article</td><td>Contraception</td><td>Acute opthalmologic complications during the use of oral contraceptives.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4140468/" target="_blank">4140468</a></td><td>1974</td><td>Article</td><td>Modern problems in ophthalmolo</td><td>Colour vision and the &#x27;pill&#x27;.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4503506/" target="_blank">4503506</a></td><td>1972</td><td>Article</td><td>American journal of optometry </td><td>The adverse effects of commonly used systemic drugs on the human eye. II.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1183645/" target="_blank">1183645</a></td><td>1975</td><td>Article</td><td>Fertility and sterility</td><td>Ocular effects of oral contraceptives. I. Studies in the dog.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/810372/" target="_blank">810372</a></td><td>1975</td><td>Article</td><td>Fertility and sterility</td><td>Ocular effects of oral contraceptives. II. Studies in the rhesus monkey.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6514354/" target="_blank">6514354</a></td><td>1984</td><td>Article</td><td>Orvosi hetilap</td><td>[Arterial occlusion in the ocular fundus induced by oral contraceptives].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/760040/" target="_blank">760040</a></td><td>1979</td><td>Article</td><td>Orvosi hetilap</td><td>[Overdose of oral contraceptive causing neurologic complications].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1251482/" target="_blank">1251482</a></td><td>1976</td><td>Article</td><td>Ugeskrift for laeger</td><td>[Retinal damage and oral contraceptives].</td></tr>
</tbody>
</table>

</div>
</details>


## 台灣上市資訊

| 項目 | 內容 |
|------|------|
| 許可證字號 | 衛署藥製字第018095號 |
| 中文品名 | 亞卡南爾非滅錠 |
| 英文品名 | ACARNAN-F |
| 許可證持有者 | 南光化學製藥股份有限公司 |
| 劑型 | 錠劑 |
| 核准適應症 | 避孕、月經異常 |

**其他上市產品**：
- 衛署藥輸字第017959號：ETHYNODIOL DIACETATE (原料藥)

## 安全性考量

### 已知風險
- **血栓栓塞風險**：所有口服避孕藥的主要風險
- **心血管風險**：35 歲以上吸菸者風險顯著增加
- **肝臟影響**：可能影響肝功能指標
- **情緒變化**：部分使用者報告情緒波動

### 藥物交互作用
根據藥理學資料：
- CYP3A4 誘導劑（如 rifampin, carbamazepine）：可能降低避孕效果
- 抗生素：部分抗生素可能影響腸肝循環

### 禁忌症
- 血栓病史
- 嚴重肝病
- 雌激素依賴性腫瘤
- 不明原因陰道出血
- 妊娠

### 特殊族群
- **孕婦**：禁用(X 級)
- **哺乳**：可能影響乳汁分泌
- **青少年**：月經初潮後可使用

## 結論與下一步

### 整體評估
此預測**具有臨床應用潛力**，原因如下：
1. 藥理機轉明確且合理
2. 多篇文獻提供觀察性證據支持
3. 同類藥物已有 FDA 核准用於痤瘡適應症
4. 安全性資料完整

### 建議行動
- [ ] 考慮對有避孕需求且合併痤瘡的女性優先選用
- [ ] 在台灣申請痤瘡適應症需要額外臨床試驗數據
- [ ] 可參考其他已核准用於痤瘡的口服避孕藥處方建議

### 臨床建議
對於需要避孕且有痤瘡困擾的女性，ethynodiol diacetate 複方製劑可作為一線選擇，可同時達到避孕和改善膚質的雙重效益。

### 風險等級
**低至中等風險** - 在適當患者選擇下可考慮使用

---

*報告生成日期：2026-02-11*
*資料來源：TxGNN 預測、ClinicalTrials.gov、PubMed、TFDA*


---

## 相關藥物報告

- [Belimumab]({{ "/drugs/belimumab/" | relative_url }}) - 證據等級 L5
- [Nitrofurantoin]({{ "/drugs/nitrofurantoin/" | relative_url }}) - 證據等級 L5
- [Berberine]({{ "/drugs/berberine/" | relative_url }}) - 證據等級 L5
- [Atracurium Besylate]({{ "/drugs/atracurium_besylate/" | relative_url }}) - 證據等級 L5
- [Benzylpenicillin]({{ "/drugs/benzylpenicillin/" | relative_url }}) - 證據等級 L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Ethynodiol Diacetate老藥新用驗證報告. https://twtxgnn.yao.care/drugs/ethynodiol_diacetate/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_ethynodiol_diacetate,
  title = {Ethynodiol Diacetate老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/ethynodiol_diacetate/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
